Swiss Cancer Institute

This study compares two standard chemotherapy regimens (bendamustine vs. fludarabine/cyclophosphamide) given before CAR-T cell therapy in 92 people with B-cell lymphoma. The goal is to see which regimen causes fewer severe side effects like cytokine release syndrome, febrile neut…

This study tests whether adding magnesium to standard chemo-immunotherapy helps people with advanced non-small cell lung cancer. About 230 participants will receive either magnesium or a placebo, without knowing which. The goal is to see if magnesium improves survival and is well…

This study looks at whether giving immunotherapy earlier in the day works better for advanced melanoma. About 108 people will be randomly assigned to morning or afternoon infusions. The goal is to see if timing improves how long the cancer stays under control, especially for wome…

This study tests a new two-drug combination for people with advanced non-small cell lung cancer whose disease got worse after standard immunotherapy and chemotherapy. The drugs—gemcitabine (a chemotherapy) and ivonescimab (a targeted therapy)—are given together to try to shrink t…